CDXC Nov 2024 7.500 call
| Previous close | 0.2100 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.5000 |
| Strike | 7.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.1000 - 0.4200 |
| Contract range | N/A |
| Volume | |
| Open interest | 424 |
Simply Wall St.Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair
Key Insights ChromaDex to hold its Annual General Meeting on 20th of June Total pay for CEO Rob Fried includes...
Business WireChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
LOS ANGELES, June 13, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC). Authorized by the U.S. FDA for compounding by 503B outsourcing facilities, pharmaceutical-grade intravenous (IV) and injectable NRC will be available in IV, shot, and push forms exclusively at clinics, with a pr
ZacksChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.
